TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
IMMX

Immix Biopharma Inc

Healthcare · Biotechnology

12.50$ -1.7% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Immix Biopharma Inc (IMMX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 78.5% of the shares are freely tradable; institutional investors hold 45.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 45.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 17.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 78.5%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 16.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 72Mio.

Largest Shareholders

Institutions

Institutions IMMX
Name Stake (%) Shares Change (%) Date
HHG PLC 6.75 4,802,002 +22.5 03/31/2026
Saturn V Capital Management LLC 6.54 4,658,429 +26.1 06/30/2026
Eventide Asset Management, LLC 5.47 3,891,019 +52.6 06/30/2026
Deep Track Capital, LP 3.90 2,775,000 +0.0 06/30/2026
Opaleye Management Inc 3.29 2,345,000 +0.0 06/30/2026
Millennium Management LLC 2.90 2,066,426 +18.1 06/30/2026
Vanguard Capital Management, LLC 2.51 1,787,994 +0.0 03/31/2026

Funds

Funds IMMX
Name Stake (%) Shares Change (%) Date
Eventide Healthcare & Life Sciences I 5.47 3,891,019 +52.6 06/30/2026
State Street® SPDR® S&P® Biotech ETF 3.12 2,220,526 -1.1 08/31/2026
Janus Henderson Hrzn Biotec E2 USD 2.74 1,948,280 +34.1 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?